Sarah J Watmough

Suggest Changes
Learn More
OBJECTIVE Clinical presentation of chronic myeloid leukemia (CML) requires not only the deregulated tyrosine kinase BCR-ABL, but also the failure of an immune response against BCR-ABL-expressing(More)
We describe a high performance liquid chromatography (HPLC) method that separates two of the currently licenced tyrosine kinase inhibitors (TKIs); nilotinib (AMN107, Tasigna) and imatinib (STI571,(More)
Imatinib has become first-line therapy in chronic myeloid leukaemia (CML), but recent studies suggest that more than one-third of patients fail imatinib over 2–3 years. (de Lavallade et al, 2008;(More)
  • 1